NETRAMARK HOLDINGS INC.

Precision AI That Identifies the Patients Driving Clinical Trial Success

FDA-reviewed | Peer-reviewed (Nature portfolio) | Commercially deployed | CRO-embedded

TSX: AIAI | OTCQB: AINMF | FRA: PF0

CORPORATE PRESENTATION | JUNE 2026

DISCLAIMER

IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this presentation has been prepared by NetraMark Holdings Inc. ("NetraMark" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company. This presentation is not, and under no circumstances is to be construed as, a prospectus, or advertisement or an offering memorandum for securities of the Company. Prospective investors should not assume that this presentation is complete and should refer to the information about the Company set out under its profile on the System for Electronic Document Analysis and Retrieval + ("SEDAR+") and consult with their own financial, legal, tax and other business advisors before investing in the Company. The information presented herein was prepared or obtained by the Company. Nothing contained herein is, or should be relied on as, a promise or representation as to the future performance of the Company.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION AND FORWARD-LOOKING STATEMENTS: Certain statements in this presentation constitute forward-looking statements and forward looking information within the meaning of applicable Canadian securities legislation (collectively herein referred to as "forward-looking statements"), which can often be identified by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate" and other words indicating that the statements are forward-looking. These include statements regarding: the ability of our NetraAI technology to leverage a sponsor's clinical trial data readouts to identify subpopulations driving drug response, placebo response and adverse events and subsequent trial strategies, potential savings to sponsors of Netramark discoveries and ability to ensure successful pivotal studies and commercial launches, future availability of the NetraAI product to Worldwide sponsors across all therapeutic areas and trial phases, the potential momentum in contract backlog and revenue associated with it, strengthening demand for differentiated AI-driven solutions in clinical trials, accelerated engagement cycles from recent proof-of-concept wins, the outcome and benefits of the Critical Path Innovation Meeting with the FDA, the pace of development of our pipeline, the expected size of Netramark leads from Phase 2 data readouts, the potential benefits of the patient adjudication and paradoxical patient/site identification product solutions, projected recognized revenues and total deal value contracted;; the extrapolation of valuation multiples.

Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties include, among others, the risk factors set out below under "Risk Factors".

These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements which are based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. Forward-looking statements contained in this presentation are made as of the date hereof and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Investors should consider the risks of this investment and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, including statements regarding total deal value contracted and projected recognized revenues, as with forward-looking statements generally, they are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Note Regarding Forward-Looking Information and Forward-Looking Statements" and under the heading "Risk Factors" below, among others. Such statements are based on several assumptions which may prove to be incorrect, including but not limited to, assumptions about: general business and economic conditions, the demand for our services, the effectiveness of our technology, the number and the frequency of meetings with potential customers, the percentage of small, medium and larger prospects (by revenue), the expected time to close on a deal, the lead conversion rate, the project value and timing of recognition of revenues associated with any customer agreements, our pace of delivery of results, and our ability to attract and retain key personnel which are important to the relationships we will pursue and our cash needs. Although NetraMark believes that these assumptions were reasonable when made, because these assumptions are subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company's control, NetraMark cannot assure that it will achieve the projections described in the forward looking statements. The process for estimating the Company's revenue requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other events and factors may materially affect the Company's financial condition or results of operations. The purpose of the financial outlooks included herein are to provide information about management's current expectations and plans relating to the future. The information may not be appropriate for other purposes.

The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue may differ materially from what is provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual financial position or results of operations.

THIRD PARTY INFORMATION: This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

Cautionary Note to United States Investors

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered and sold in the United States (as defined in Regulation S under the U.S. Securities Act) except pursuant to an exemption from the registration requirements of the U.S. Securities Act. The information herein is not for distribution and does not constitute an offer to buy any securities within the United States.

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY, INCLUDING THE MERITS AND RISKS INVOLVED.

Any such securities sold in the United States will be "restricted securities" within the meaning of Rule 144 under the U.S. Securities Act. Such securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act.

Readers should be aware that the acquisition, holding or disposition of the securities described herein may have tax consequences both in Canada and the United States. The tax consequences of the acquisition, holding or disposition of such securities are not described herein. Consequently, any prospective investor is advised to consult their own tax advisors regarding the application of federal income tax laws to their particular circumstances, as well as any state, provincial, local, foreign and other tax consequences of investing in the securities described herein and acquiring, holding or disposing of such securities. Investing in the securities described herein involves risks. An investment in such securities is suitable only for investors who fully understand, and are capable of bearing, the risks of such investment. Prospective investors should review and consider carefully the information disclosed in SEDAR+ documents, including any risk factors described therein.

Investing in the securities described herein involves risks. An investment in such securities is suitable only for investors who fully understand, and are capable of bearing, the risks of such investment. Prospective investors should review and consider carefully the information disclosed in SEDAR+ documents, including any risk factors described therein.

RISK FACTORS

RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business. If any of the following risks actually occur, the Company's business may be harmed, and its financial condition and outlooks and results of operations may suffer significantly.

- NetraMark has a history of operating losses, and we expect to continue to incur losses over the next several years.
- NetraMark's limited operating history may make it difficult for you to evaluate the success of its business to date and to assess our future viability, which may depend on us obtaining additional capital, which might not be available on economically acceptable terms, or at all.
- Our interim and annual results may fluctuate significantly, which could adversely impact the value of our common shares.
- NetraMark's sales and financial forecasts may prove to be inaccurate. We may need to raise additional capital, which may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.
- We are substantially dependent on the NetraMark products to deliver our products and services. The NetraMark platform may fail to discover valued enrichment criteria that positively impact the clinical trial process for our clients.
- Defects or disruptions in the NetraMark products and its associated algorithms and machine learning models could result in diminishing efficacy of our sub-population identification work and therefore we may discover a reduction in our revenues.
- If we cannot maintain existing clients and/or attract new clients or enter into new collaborations, our business could be adversely affected.
- We face competition, which may result in others discovering AI based methods that are more successful than ours, requiring us to rapidly adapt our approach and implement significant technological change and respond to introductions of new products and technologies by competitors to remain competitive.
- Pre-clinical and clinical development involves a lengthy and expensive process with uncertain outcomes. Our strategic partners' pre-clinical and clinical programs may experience delays or may never advance, which would adversely affect their ability or interest to engage or utilize the NetraMark technology.
- Our internal information technology systems, or those of our third-party vendors (including providers of cloud-based infrastructure), contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.
- The Company's insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which the Company is exposed. If the Company were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if the Company were to incur such liability at a time when it is not able to obtain liability insurance, its business, results of operations and financial condition could be materially adversely affected.
- The effects of health epidemicsin regions where we, or the third parties on which we rely, have business operations could adversely impact our business as well as the business or operations of third parties with whom we conduct business.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.
- The regulatory approval processes of the relevant regulatory authorities are lengthy, time consuming and inherently unpredictable. If the third parties with which we work are not able to obtain, or if there are delays in obtaining, required regulatory approvals for their drug candidates, they will not be able to commercialize, or will be delayed in commercializing, drug candidates, and our ability to generate revenue will be materially impaired.
- NetraMark has invested, and we expect to continue to invest, in research and development efforts that further enhance our technology. If the return on these investments is lower or develops more slowly than we expect, our revenue and results of operations may suffer.
- The market opportunities for clients that may use the NetraMark technology may be smaller than we anticipated.
- NetraMark has in the past, and we may in the future, acquire other companies or technologies, which could divert our management's attention, result in additional dilution to our shareholders and otherwise disrupt our operations and adversely affect our operating results.
- Past performance by any member or members of our management team, board of directors and advisory board may not be indicative of future performance.
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel including to achieve our business development goals.
- We may be unable to manage our current and future growth effectively, which could make it difficult to execute our business strategy.
- If securities or industry analysts do not publish research or publish inaccurate or unfavourable research about our business, our share price and trading volume could decline.
- Current and future healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
- Current and future artificial intelligence legislative reform measures may have a material adverse effect on our business and results of operations.
- If we are unable to obtain, maintain, enforce and protect our intellectual property, competitors could develop and commercialize technology and products similar or identical to ours, the value of our business, may be adversely affected.
- Some elements of the NetraMark technology relies on third-party software, including open-source software ("OSS"), and any failure to comply with the terms of one or more of our commercial OSS licenses could adversely affect our business, subject us to litigation, or create potential liability.
- Our registered trademarks or unregistered brands or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks.
- We or our existing or future collaborators may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time consuming and unsuccessful. Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- Our internal controls may not be sufficiently developed to prevent errors (including accounting- and tax-related errors), inefficiencies and compliance violations. If we discover deficiencies in our internal control systems, we may be required to undertake corresponding corrections, incur unexpected costs and trust in our business and operations may be adversely affected. If we fail to comply with applicable laws and regulations, we may breach representations made to our collaborators, and regulatory authorities may require us to take remedial action. In addition, such violations may be punishable by criminal and civil sanctions, including substantial fines, and harm our reputation.
- There may not be a liquid market for our common shares that will persist. Consequently, investors may not be able to sell their common shares at or above the price at which they acquired them. The price of the common shares may be volatile, and investors may lose all or part of their investments.

The Problem

Pharma Companies Collect Massive Trial Data — But Miss the Signals That Matter

Up to 65%

of late-stage trials fail

driven by enrolling the wrong patient population

<12%

FDA overall approval rate

most programs never reach the finish line

ONE-THIRD OF TRIAL DATA IS NEVER USED

One-third of all data collected in Phase 2 and Phase 3 clinical trials is not required by regulators and is not used to support primary or secondary endpoints.

Source: TransCelerate BioPharma & Tufts CSDD (2025)

THE DATA HOLDS THE ANSWER — BUT TRADITIONAL METHODS CAN'T FIND IT

Traditional analyses average across the entire population, missing the patient-level signals that determine whether a drug works. The problem isn't a lack of data. It's a lack of the right analysis.

Sources: Chart Pack Biopharmaceuticals in Perspective (2020); TransCelerate BioPharma & Tufts CSDD, Therapeutic Innovation & Regulatory Science (2025); Fierce Biotech (2025).

The Solution — NetraAI

Explainable AI That Finds Who Is Driving the Signal

THE OPPORTUNITY: The data to identify the right patients already exists inside these trials. What's missing is an AI platform purpose-built to find the signal in small, noisy, heterogeneous datasets — **that's NetraAI.**

Proven Results

From Failed Signals to Precision Treatment Effects

Positive Phase 2 Results



Visit	N	Cohen's d	p-value
Day 7	61	0.80	0.01
Day 14	54	0.90	0.01

Negative Phase 3 Results



Visit	N	Cohen's d	p-value
Day 7	214	0.153	0.264
Day 14	208	0.154	0.280
Day 28	208	0.082	0.558

NetraMark's Predictive Phase 2 Results



Visit	N	Cohen's d	p-value
Day 7	22/40 (55%)	1.03	0.02
Day 14	23/39 (59%)	1.07	0.02

NetraMark's Predictive Phase 3 Results



Visit	N	Cohen's d	p-value
Day 7	133/214 (62%)	0.524	0.002
Day 14	128/208 (62%)	0.386	0.029
Day 28	126/208 (61%)	0.346	0.053

What NetraAI found: Two small, clinically interpretable changes to standard eligibility criteria — removal of subjects with (1) a Baseline Score of 0 on HAMD SS GI, and (2) Systolic BP of 137–143 — transformed a failed trial signal into a meaningful treatment effect. A 4x improvement in effect size.

7

Competitive Moat

Why This Cannot Be Easily Replicated

FDA MEETING (CPIM) — NO OTHER AI HAS THIS

NetraAI is the only clinical trial AI platform to have undergone a closed-door FDA Critical Path Innovation Meeting. No traditional AI, ML, Bayesian, or standard statistical approach has achieved this level of regulatory engagement.

PURPOSE-BUILT FOR CLINICAL TRIALS

Unlike general-purpose AI tools, NetraAI was designed from the ground up for small, high-dimensional datasets. It produces explicit variable bundles and patient membership every run — generating Model-Derived Subgroups defined by 2–4 interpretable variables.

REGULATORY DEFENSIBILITY FRAMEWORK

Published five-component Regulatory Defensibility Index (RDI) designed for FDA's emerging AI-native review environment (Elsa/HALO). Stress-tests subgroup claims across stability, fragility, placebo structure, mechanistic coherence, and evidence calibration.

Scientific Foundation

Peer-Reviewed, Publication-Backed

2025 / 2026

CORE COLLABORATIONS

NIMH / MAYO / FMP Europe / CAMH

Dec 2025

npj DIGITAL MEDICINE (NATURE PORTFOLIO)

Peer-reviewed publication demonstrating explainable patient subpopulation discovery in clinical trial data.

May 2026

REGULATORY DEFENSIBILITY

HALO/ELSA FDA Regulatory Defensibility Framework with five-component RDI.

2019–2026

11+ PUBLICATIONS & PRESENTATIONS

Spanning psychiatry, oncology, CNS. ASCP 2026 plenary panel. Drs. Geraci, Pani, Qorri.

Total Addressable Market

~34,500 Active Phase 2 & Phase 3 Trials Globally

REVENUE OPPORTUNITY

At C$300,000 average engagement price

Phase 2:	C$7.2B
Phase 3:	C$3.2B
TOTAL:	**C$10.4 BILLION[1]**

~34,500 trials × C$300K = C$10.4B
Even capturing a fraction represents a transformative opportunity.

Sources: ClinicalTrials.gov API (June 2026); EU Clinical Trials Register; WHO ICTRP coverage ratios. Average engagement: C$300K (NetraMark current pricing). TAM assumes one engagement per active trial.
1. Company estimates based on 100% of the TAM at an approximate cost of C$300,000 per project

Commercialization Strategy

Two Routes to Market — Direct + Channel Partners

DIRECT TO SPONSORS

- Phase 2 readout analysis leading to Phase 3 trial decisions
- Phase 3 readout analysis leading to market access phase
- C$250–350K per 6-week engagement
- 40+ active opportunities in pipeline
- 7+ proposals/contracts in progress
- 10 repeat contracts with NASDAQ-listed biopharma client

CHANNEL PARTNERS

- Worldwide Clinical Trials: MSA executed, QA complete (Oct 2025)
- NetraAI embedded in WCT Phase 2/3 bids across CNS and oncology
- Scalable model: NetraAI included in CRO proposals as standard service
- Expands reach to global sponsor base without direct sales overhead
- Additional CRO partnerships being explored

Leadership Team

Proven Expertise Across AI, Pharma, Regulatory, and Capital Markets

George Achilleos
Chief Executive Officer

Seasoned business executive with 25+ years of experience in the technology sector

Josh Spiegel
President

25+ years of experience in finance, sales and corporate strategy, with a strong background in healthcare, business services, and technology

Dr. Joseph Geraci
Chief Technology Officer/Chief Scientific Officer and Director

Co-founder of NetraMark, PhD mathematician, medical scientist, and quantum machine learning specialist

Dr. Luca Pani
Chief Innovation and Regulatory Officer

Former director-general of the Italian Medicines Agency (AIFA)

Dr. Panteli Theocharous
Chief Medical Officer

C-Suite Executive, Board Chair/Director, Biotech co-Founder, Strategic Advisor, CYDIA Award Winner

Angelico Carta
Chief Strategy Officer

35 years of industry experience, including co-founder and President of Worldwide Clinical Trials

Tale of the Tape

Capital Structure & Market Data

Shares Outstanding	**91.8 million**
52-Week Range	**C$0.68 – $1.10**
Insider Ownership	**~22 million shares (fully diluted)**
Listings	**TSX: AIAI | OTCQB: AINMF | FRA: PF0**

Source: TMX Money. Market data as of last available. Subject to change.

Thank You

George Achilleos | CEO
george@netramark.com
netramark.com

TSX: AIAI | OTCQB: AINMF | FRA: PF0